Praxis Precision Medicines, Inc. (PRAX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | - | - | 302 | 357 |
| Research and development | 63,006 | 60,806 | 41,881 | 27,260 |
| General and administrative | 13,061 | 13,922 | 15,256 | 10,585 |
| Total operating expenses | 76,067 | 74,728 | 57,137 | 37,845 |
| Loss from operations | -76,067 | -74,728 | -56,835 | -37,488 |
| Other income, net | 4,940 | 5,432 | 4,925 | 4,811 |
| Total other income | 4,940 | 5,432 | 4,925 | 4,811 |
| Net loss | -71,127 | -69,296 | -51,910 | -32,677 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -3.31 | -3.29 | -2.75 | -1.74 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -3.31 | -3.29 | -2.75 | -1.74 |
| Weighted average common shares outstanding, basic (in shares) | 21,474,827 | 21,055,834 | 18,884,562 | 18,824,479 |
| Weighted average common shares outstanding, diluted (in shares) | 21,474,827 | 21,055,834 | 18,884,562 | 18,824,479 |